
The FDA approved an IDE allowing Mercy BioAnalytics to evaluate its Evident blood-based ovarian cancer screening test in the prospective pivotal SOARA study of average-risk women.
Recent advancements in nucleic acid amplification tests (NAATs) have enabled clinicians to diagnose patients with improved accuracy for important pathogens. But are clinicians impeded by common misconceptions about available tools, or even key differences between DNA and RNA?
This supplement accurately explains the science of RNA-based testing modalities and reviews methods and results of assays for Mycoplasma genitalium, bacterial vaginosis, vulvovaginal candidiasis, Trichomonas vaginalis, and human papillomavirus.






